NEW DATE - CDER SBIA Webinar on FDA’s Proprietary Name Review

FDA Division of Drug Information: Know the Moment It Happens

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.


On Tuesday July 15, 2014 at 11:00 am EDT, CDER Small Business and Industry Assistance (CDER SBIA) will host a webinar entitled Overview of FDA’s Proprietary Name Review Process.”

 

FDA published a notice in the Federal Register announcing the availability of the draft Guidance for Industry - Best Practices in Developing Proprietary Names for Drugs. The draft guidance provides a qualitative systematic framework for evaluating proprietary names before submitting them for FDA review. FDA is issuing this guidance to help sponsors of drug and biological products develop proprietary names that are not potentially misleading and do not cause or contribute to medication errors.

This webinar is to provide an overview of the Proprietary Name Review guidance that focuses on the safety aspects in the development and selection of proposed proprietary names for all prescription and nonprescription drug products and biological products.

To register for this Event, please go the following link: https://collaboration.fda.gov/sbia070714/event/registration.html

(Registration password needs to be 8 characters and alphanumeric)

Note: Your registration acknowledgement will include the webinar access link.

 

Audio will broadcast from your computer speakers.

Closed captioning will be provided.

Please note: There is a user capacity limit for this webinar. For those who cannot enter the webinar, please know that it will be recorded and a link will be posted to this page.

Questions/Comments can be submitted live via a Q/A chat window.

For questions concerning the webinar, please contact CDER SBIA at:

(866)-405-5367 | (301)-796-6707


This is an automated message delivery system.  Replying to this message will not reach DDI staff.  If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday.  You can also email us at druginfo@fda.hhs.gov.


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery